Market access round-up: the UK opens up to innovationWhen it comes to market access in the UK, the public’s eye has mostly been on the ongoing Share XMarket access round-up: the UK opens up to innovationhttps://pharmaphorum.com/views-and-analysis/market-access-roundup-the-uk-opens-up-to-innovation/
NICE backs Ocrevus for PPMS in England – but with caveatsPatients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for Share XNICE backs Ocrevus for PPMS in England – but with caveatshttps://pharmaphorum.com/news/nice-backs-ocrevus-for-ppms-in-england-but-with-caveats/
NICE recommends Roche’s Tecentriq combo for certain lung cancer patientsCertain patients with untreated lung cancer in England have a new treatment option after cost-effectiveness body NICE made Share XNICE recommends Roche’s Tecentriq combo for certain lung cancer patientshttps://pharmaphorum.com/news/nice-recommends-roches-tecentriq-combo-for-certain-lung-cancer-patients/
NICE launches new tool to identify promising digital and medical techNICE has launched a new resource to help identify and support new health technologies for the UK health Share XNICE launches new tool to identify promising digital and medical techhttps://pharmaphorum.com/news/nice-launches-new-tool-to-identify-promising-digital-and-medical-tech/
Many patients still denied cancer drugs in UK, survey findsThe Institute for Cancer Research has called for action to improve access to innovative cancer treatments after a Share XMany patients still denied cancer drugs in UK, survey findshttps://pharmaphorum.com/news/many-patients-still-denied-cancer-drugs-in-uk-survey-finds/
NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayNICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in Share XNICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayhttps://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/
Scotland backs Aimovig for migraine after NICE says noPeople suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig Share XScotland backs Aimovig for migraine after NICE says nohttps://pharmaphorum.com/news/scotland-backs-aimovig-for-migraine-after-nice-says-no/
NICE recommends interim funding for Lilly’s breast cancer drugFinal draft guidance from NICE has recommended interim NHS funding for Eli Lilly’s Verzenios (abemaciclib) with fulvestrant, giving Share XNICE recommends interim funding for Lilly’s breast cancer drughttps://pharmaphorum.com/news/nice-recommends-interim-funding-for-lillys-breast-cancer-drug/
NICE backs funding for MSD’s diabetes drug SteglatroNICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro Share XNICE backs funding for MSD’s diabetes drug Steglatrohttps://pharmaphorum.com/news/nice-backs-funding-for-msds-diabetes-drug-steglatro/
